Novel Therapy Target in Metastatic Prostate Cancer

Launched by FUDAN UNIVERSITY · Oct 10, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for men with metastatic prostate cancer, specifically a type called metastatic castration-resistant prostate cancer (mCRPC). The researchers will use advanced techniques to study the cancer's molecular characteristics, which means they want to understand the unique features of the cancer at a cellular level. They will also create models in the lab, including miniaturized versions of the tumors and animal models, to help identify new drug targets that could lead to better treatments.

To participate in this study, men aged 65 to 74 who have been diagnosed with prostate cancer that has spread to other parts of the body may be eligible. They need to have confirmation of their cancer through medical imaging and be able to undergo surgery or a biopsy (a procedure to take a small sample of tissue). It's important that participants can understand the study and give their consent to take part. The study is not yet recruiting participants, but it aims to contribute valuable information that could improve future treatment options for men facing this challenging condition.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed prostate cancer
• • 2. metastatic disease confirmed by image examination
• • 3. Patients who can undergo surgery or biopsy for prostate cancer
• • 4. Able to provide informed consent
• Exclusion Criteria:
• • 1. Patients diagnosed with other types of cancer besides prostate cancer
• • 2. Not accessible to surgery sample
• • 3. Patients fail to provide informed consent
• • 4. Other situation that researchers think are unsuitable for this study